Cue Biopharma, Inc.: share-based compensation expense
Share-based compensation expense for Cue Biopharma, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Cue Biopharma, Inc. financial histories
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 4,744,000 | USD | 2026-03-16 | 10-K · 0001193125-26-108287 |
| 2024-01-01 | 2024-12-31 | 6,846,000 | USD | 2026-03-16 | 10-K · 0001193125-26-108287 |
| 2023-01-01 | 2023-12-31 | 8,180,000 | USD | 2025-03-31 | 10-K · 0000950170-25-047677 |
| 2022-01-01 | 2022-12-31 | 9,496,000 | USD | 2024-03-28 | 10-K · 0000950170-24-038059 |
| 2021-01-01 | 2021-12-31 | 11,515,584 | USD | 2023-03-21 | 10-K · 0000950170-23-008927 |
| 2020-01-01 | 2020-12-31 | 10,480,782 | USD | 2022-03-16 | 10-K · 0000950170-22-003969 |
| 2019-01-01 | 2019-12-31 | 6,520,982 | USD | 2021-03-09 | 10-K · 0001564590-21-011777 |
| 2018-01-01 | 2018-12-31 | 7,173,713 | USD | 2020-03-12 | 10-K · 0001564590-20-010212 |
| 2017-01-01 | 2017-12-31 | 2,775,363 | USD | 2019-03-14 | 10-K · 0001564590-19-007832 |
Related financial histories
- Cue Biopharma, Inc.: total assets
- Cue Biopharma, Inc.: total liabilities
- Cue Biopharma, Inc.: stockholders equity
- Cue Biopharma, Inc.: cash and cash equivalents
- Cue Biopharma, Inc.: net income or loss
- Cue Biopharma, Inc.: operating cash flow
- Cue Biopharma, Inc.: capital expenditure payments
- Cue Biopharma, Inc.: contract revenue excluding tax
- Cue Biopharma, Inc.: financing cash flow
- Cue Biopharma, Inc.: investing cash flow
- Cue Biopharma, Inc.: retained earnings or deficit
- Cue Biopharma, Inc.: basic weighted-average shares
- Cue Biopharma, Inc.: diluted weighted-average shares
- Cue Biopharma, Inc.: basic earnings per share
- Cue Biopharma, Inc.: diluted earnings per share
- Cue Biopharma, Inc.: income tax expense or benefit
- Cue Biopharma, Inc.: net property, plant and equipment
- Cue Biopharma, Inc.: operating income or loss
- Cue Biopharma, Inc.: current assets
- Cue Biopharma, Inc.: interest expense
- Cue Biopharma, Inc.: current liabilities
- Cue Biopharma, Inc.: current accounts payable
- Cue Biopharma, Inc.: net current accounts receivable
- Cue Biopharma, Inc.: common-stock repurchase payments
- Cue Biopharma, Inc.: operating expenses
- Cue Biopharma, Inc.: research and development expense
Inspect the source
- Entity
- Cue Biopharma, Inc. / CIK 0001645460
- Captured
- 2026-09-21T17:21:45.136Z
- SEC response SHA-256
ea8103701b13d2e83c3b2cb38106acb79e62f59815381c1dbdcbb1b39dc552a2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001645460.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))